Tb Drug Development

每年评估约4000至5000种化合物对结核分枝杆菌的抗菌生长抑制活性。

Evaluate approximately 4,000 to 5000 compounds per year for antimicrobial growth-inhibition activity against Mycobacterium tuberculosis. Improve, standardize, and adopt new assays for determining the activity of compounds against dormant (slowly growing, persistent, or quiescent) M. tuberculosis organisms. Evaluate approximately 1000 selected compounds per year for inhibition of replication of intracellular M. tuberculosis. Evaluate therapeutic agents for efficacy against M. tuberculosis in an infected mammalian cell culture test system. This system must also provide a quantitative assessment of cytotoxicity of compounds for control, uninfected mammalian cells. Develop and implement biochemical, target-specific Mycobacterium tuberculosis drug screening assays in a high-throughput Format Develop and implement M. tuberculosis metabolic stage-specific drug screening assays in a high-throughput format. Using published computational or neural network methods, design and implement an in silico system for predicting drug characteristics such as solubility, human intestinal absorption, bioavailability, and potential toxicities for therapeutic against against M. tuberculosis